Sequana Medical has initiated a subscription request for up to EUR 20 million under an agreement with GEM Global Yield to support its innovative therapies for drug-resistant fluid overload.

Target Information

Sequana Medical NV, a leader in addressing drug-resistant fluid overload associated with liver disease, heart failure, and cancer, has announced the issuance of a subscription request notice as part of its share subscription facility agreement with GEM Global Yield LLC SCS. Founded on innovative therapeutic solutions, Sequana Medical is committed to improving treatment outcomes for patients suffering from conditions that render standard treatment options like diuretics ineffective, thereby enhancing both their quality of life and clinical outcomes.

The company aims to provide much-needed relief to a growing population of patients who experience serious complications, including increased mortality and reduced mobility. Its proprietary platforms, alfapump® and DSR®, have demonstrated significant potential, offering innovative treatments tailored to the needs of patients who are considered diuretic-resistant. Recently, Sequana Medical received FDA approval for the alfapump System, further laying the groundwork for its expansion into the United States.

Industry Overview

In Belgium, the healthcare system is characterized by a high standard of care, supported by advanced medical technologies and pharmaceuticals. The country boasts a robust framework for healthcare innovations, encouraging companies like S